Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Nov 18;8:3361–3369. doi: 10.2147/OTT.S89275

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Zhang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Meta-analysis (Forest plot) of 50 studies assessing Bcl-2 in NSCLC.

Notes: (A) Forest plot of stage I group analysis; pooled data from eight studies did not show significant impact on survival with Bcl-2-positive expression compared with those with Bcl-2-negative expression (HR 0.93, 95% CI 0.80–1.07, P=0.50). (B) Forest plot of stage I–III group analysis; pooled data from 29 studies showed that NSCLC patients with Bcl-2-positive expression have better prognosis than those with Bcl-2-negative expression (HR 0.77, 95% CI 0.69–0.89, P<0.0001). (C) Forest plot of stage III–IV group analysis; pooled data from eight studies showed that patients with Bcl-2-positive expression have better prognosis than those with Bcl-2-negative expression (HR 0.74, 95% CI 0.59–0.94, P=0.01). (D) Forest plot of all stage group analysis; pooled data from 13 studies did not show significant impact on survival in patients with Bcl-2-positive expression compared with those with Bcl-2-negative expression (HR 0.84, 95% CI 0.69–1.02, P=0.08). (E) Forest plot of SCC group analysis; pooled data from seven studies showed that patients with Bcl-2-positive expression have better prognosis than those with Bcl-2-negative expression (HR 0.54, 95% CI 0.32–0.90, P=0.02). (F) Forest plot of adenocarcinoma group analysis; pooled data from six studies did not show significant impact on survival in patients with Bcl-2-positive expression compared with those with Bcl-2-negative expression (HR 0.92, 95% CI 0.56–1.51, P=0.73).

Abbreviations: Bcl-2, B-cell-lymphoma-2; NSCLC, non-small-cell lung cancer; HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma.

Meta-analysis (Forest plot) of 50 studies assessing Bcl-2 in NSCLC.

Notes: (A) Forest plot of stage I group analysis; pooled data from eight studies did not show significant impact on survival with Bcl-2-positive expression compared with those with Bcl-2-negative expression (HR 0.93, 95% CI 0.80–1.07, P=0.50). (B) Forest plot of stage I–III group analysis; pooled data from 29 studies showed that NSCLC patients with Bcl-2-positive expression have better prognosis than those with Bcl-2-negative expression (HR 0.77, 95% CI 0.69–0.89, P<0.0001). (C) Forest plot of stage III–IV group analysis; pooled data from eight studies showed that patients with Bcl-2-positive expression have better prognosis than those with Bcl-2-negative expression (HR 0.74, 95% CI 0.59–0.94, P=0.01). (D) Forest plot of all stage group analysis; pooled data from 13 studies did not show significant impact on survival in patients with Bcl-2-positive expression compared with those with Bcl-2-negative expression (HR 0.84, 95% CI 0.69–1.02, P=0.08). (E) Forest plot of SCC group analysis; pooled data from seven studies showed that patients with Bcl-2-positive expression have better prognosis than those with Bcl-2-negative expression (HR 0.54, 95% CI 0.32–0.90, P=0.02). (F) Forest plot of adenocarcinoma group analysis; pooled data from six studies did not show significant impact on survival in patients with Bcl-2-positive expression compared with those with Bcl-2-negative expression (HR 0.92, 95% CI 0.56–1.51, P=0.73).

Abbreviations: Bcl-2, B-cell-lymphoma-2; NSCLC, non-small-cell lung cancer; HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma.